Abstract
This editorial summarizes insights expressed at a recent symposium on angiotensin receptor blockers that is now published in this supplement. After a series of seminal trials in 2001 and 2002 in patients with such conditions as type 2 diabetes and renal insufficiency, heart-failure and hypertension with left-ventricular hypertrophy, we have evidence that these agents confer blood-pressure independent protective effects across the cardiovascular and renal continuum. Even so, blood-pressure control remains a key target of treatment and improving treatment compliance is a further priority. Forthcoming clinical trials with angiotensin receptor blockers in post-myocardial infarction patients and in high risk hypertension should give additional guidance in optimizing cardiovascular protection and prognosis. © 2003 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
